(Q42389372)

English

Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically

scientific article published on March 1994

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically (English)

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Cortesina G

1

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

De Stefani A

2

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

Galeazzi E

3

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

Cavallo GP

4

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

Badellino F

5

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

Margarino G

6

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

Jemma C

7

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

Forni G

8

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

language of work or name

0 references

publication date

1 March 1994

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

69

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

3

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

572-576

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

https://scigraph.springernature.com/pub.10.1038/bjc.1994.104

0 references

Delayed hypersensitivity reactions in patients with squamous cell cancer of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968846

28 May 2018

Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968846

28 May 2018

In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968846

28 May 2018

Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968846

28 May 2018

Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968846

28 May 2018

Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968846

28 May 2018

Production of leukocyte migration inhibition factor by lymphocytes of larynx cancer patients stimulated by laryngeal carcinoma solubilized membrane antigens

1 reference

https://pubmed.ncbi.nlm.nih.gov/8123489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of blocking mechanisms against immunological responses in patients with laryngeal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8123489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunomodulators as local hormones: new insights regarding their clinical utilization

1 reference

https://pubmed.ncbi.nlm.nih.gov/8123489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity

1 reference

https://pubmed.ncbi.nlm.nih.gov/8123489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically

1 reference

https://pubmed.ncbi.nlm.nih.gov/8123489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8123489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/8123489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1994.104

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

29 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42389372&oldid=1944061923"